Embed

Academic

Authors

Lori M. Minasian

Lori M. Minasian,National Institutes of Health, United States,Oncology,Genetics & Genealogy,Family Medicine

Edit

Lori M. Minasian

National Institutes of Health, United States

Publications: 42 | Citations: 1078

Fields: Oncology, Genetics & Genealogy, Family Medicine

Collaborated with 240 co-authors from 1992 to 2011 | Cited by 3662 authors

Cumulative Annual

Sort by:

Publications (42)

BibTeX | RIS | RefWorks Download

Stakeholder perspectives on implementing the National Cancer Institute’s patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

, , , , , , , , , , , http://academic.research.microsoft.com/io.ashx?type=5&id=48604932&selfId1=23862238&selfId2=0&maxNumber=12&query=

Published in 2011.

Translating research into evidence-based practice: The National Cancer Institute Community Clinical Oncology Program (Citations: 2)

, , , , , , , , ,

Journal: Cancer , 2010

Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2 (Citations: 7)

, , , , , , , , , ,

Journal: Clinical Cancer Research - CLIN CANCER RES , vol. 16, no. 2, pp. 664-672, 2010

Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity (Citations: 4)

, , , , , , , ,

Journal: British Journal of Cancer - BRIT J CANCER , vol. 102, no. 3, pp. 495-499, 2010

Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer (Citations: 4)

, , , , , , , , ,

Journal: Cancer , vol. 116, no. 6, pp. 1476-1484, 2010

Sort by:

Citations (1078 times by 1001 publications)

Integration of Pharmacogenetics and Pharmacogenomics in Drug Development: Implications for Regulatory and Medical Decision Making in Pediatric Diseases

, , , , , , , , ,

Journal: Journal of Clinical Pharmacology - J CLIN PHARMACOL , vol. 52, no. 5, pp. 704-716, 2012

Averaged Differential Expression for the Discovery of Biomarkers in the Blood of Patients with Prostate Cancer

, , , , , ,

Journal: PLOS One , vol. 7, no. 4, 2012

Multilevel Bayesian Models for Survival Times and Longitudinal Patient-Reported Outcomes with Many Zeros

, , ,

Journal: Journal of The American Statistical Association - J AMER STATIST ASSN , vol. just-accep, no. just-accep, 2012

Methylseleninic Acid Enhances Paclitaxel Efficacy for the Treatment of Triple-Negative Breast Cancer

, , , , , ,

Journal: PLOS One , vol. 7, no. 2, 2012

The Antioxidants Vitamins A and E and Selenium Do Not Reduce the Incidence of Asbestos-Induced Disease in a Mouse Model of Mesothelioma

, , , ,

Journal: Nutrition and Cancer-an International Journal - NUTR CANCER , vol. ahead-of-p, no. ahead-of-p, 2012

Comments

Co-authors (240)

Journals (20)

Keywords (77)

Lori M. Minasian,National Institutes of Health, United States,Oncology,Genetics & Genealogy,Family Medicine

Publications (42)

BibTeX | RIS | RefWorks Download

Stakeholder perspectives on implementing the National Cancer Institute’s patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Translating research into evidence-based practice: The National Cancer Institute Community Clinical Oncology Program (Citations: 2)

Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2 (Citations: 7)

Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity (Citations: 4)

Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer (Citations: 4)

Citations (1078 times by 1001 publications)

Integration of Pharmacogenetics and Pharmacogenomics in Drug Development: Implications for Regulatory and Medical Decision Making in Pediatric Diseases

Averaged Differential Expression for the Discovery of Biomarkers in the Blood of Patients with Prostate Cancer

Multilevel Bayesian Models for Survival Times and Longitudinal Patient-Reported Outcomes with Many Zeros

Methylseleninic Acid Enhances Paclitaxel Efficacy for the Treatment of Triple-Negative Breast Cancer

The Antioxidants Vitamins A and E and Selenium Do Not Reduce the Incidence of Asbestos-Induced Disease in a Mouse Model of Mesothelioma


	View FAQ about top research areas and Fields of study

Lori M. Minasian,National Institutes of Health, United States,Oncology,Genetics & Genealogy,Family Medicine

Publications (42) BibTeX | RIS | RefWorks Download

Translating research into evidence-based practice: The National Cancer Institute Community Clinical Oncology Program (Citations: 2)

Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2 (Citations: 7)

Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity (Citations: 4)

Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer (Citations: 4)

Publications (42)

BibTeX | RIS | RefWorks Download